N@N

ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2011 Financial Results

^{Published on 2010-10-21 03:40:45 - Market Wire}
 

WALTHAM, Mass.--([ BUSINESS WIRE ])--[ ImmunoGen, Inc ]. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the Company will host a conference call at 4:30 p.m. ET on Thursday, October 28, 2010, to discuss ImmunoGen's financial results for the three-month period ended September 30, 2010 a" the first quarter of the Companya™s 2011 fiscal year. Management also will provide an update on the Company.

To access the live call by phone, dial 913-312-0379. Passcode: 9033489. The call also may be accessed through the Investor Information section of the Company's website, [ http://www.immunogen.com ]. Following the live webcast, a replay of the call will be available at the same location through November 4, 2010.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are currently seven TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGena™s collaborative partners include Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGen's TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing through the Company's collaboration with Genentech. More information about ImmunoGen can be found at [ www.immunogen.com ].